首页> 外文OA文献 >The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

【2h】

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

机译：每天作为起始剂量的AFATINIB 30毫克的临床疗效可能不会低于IV阶段19或外显子21突变的阶段IV肺腺癌患者的AFATINIB 40mg

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Chih-Jen Yang; Ming-Ju Tsai; Jen-Yu Hung; Mei-Hsuan Lee; Ying-Ming Tsai; Yu-Chen Tsai; Jui-Feng Hsu; Ta-Chih Liu; Ming-Shyan Huang; Inn-Wen Chong;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 22:26:50

相似文献

外文文献
中文文献

1. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations [J] . Chen Yi-Chieh, Tsai Ming-Ju, Lee Mei-Hsuan, BMC Cancer . 2021,第1期

机译：下降剂量的AFATINIB用于治疗转移性肺腺癌宿舍21和外显子19突变
2. FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN [J] . Yang Chih Jen, Tsai Ming-Ju, Hung Jen-Yu, Respirology : . 2018,第Suppla2期

机译：一线吉非替尼，厄洛替尼和Afatinib在患者中提供了类似的临床疗效，患者患有罕见的台湾罕见的EGFR突变
3. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation [J] . Yoshitaka Iwamoto, Eiki Ichihara, Naofumi Hara, Japanese journal of clinical oncology. . 2019,第8期

机译：AfaTinib治疗对肺腺癌的疗效胃外显子18德7109_t710Insd突变
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations [O] . Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, 2017

机译：在具有外显子19或外显子21突变的IV期肺腺癌患者中每天30 mg阿法替尼作为起始剂量的临床疗效可能不逊于每天40 mg的阿法替尼
6. First-Line Afatinib 30 Mg Daily and 40 Mg Daily Showed Similar Efficacy in Patients with Stage IV Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptormutation in Exon 19 or 21 [O] . J.Y. Ma, C.-J. Yang, M.-J. Tsai, 2020

机译：第一线AFATINIB每日30毫克，每日40毫克每日表现出类似的患者IV阶段肺腺癌患者的疗效，其含有外显子19或21的表皮生长因子竞争力

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

著录项

相似文献

相关主题

期刊订阅